04:54 AM EST, 11/14/2024 (MT Newswires) -- ClearPoint Neuro ( CLPT ) said late Wednesday the US Food and Drug Administration has granted de novo marketing authorization for its SmartFlow Neuro Cannula for the delivery of PTC Therapeutics' ( PTCT ) Kebilidi gene therapy to targeted regions within the brain.

Kebilidi is indicated for the treatment of aromatic L-amino acid decarboxylase deficiency, a genetic disorder that typically results in disability, the company said.

Price: 12.00, Change: +1.05, Percent Change: +9.59